There is a need to expand the spectrum of biomarkers, which are important for diagnostic, prognostic, and therapeutic response assessment, to those other than VEGF-D, several of which have recently been studied in LAM, although none are yet used in the clinical routine. Here, VEGFD is linked to lymphangioleiomyomatosis.